Vantage logo

The problem with Her2-low testing

Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.

Vantage logo

Gossamer could put pressure on Merck

The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.